RxDoctor Payments Data

Angela Snow, MD

Internal Medicine · Lafayette, LANPI 1538368345

Payments from drug & device makers

$8,095in general payments, 2019–2025

Across 551 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AbbVie$1K
  • Pfizer$797
  • AstraZeneca$559
  • Novo Nordisk$526
  • Takeda Pharmaceuticals U.S.A., Inc.$374
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$8,057100%
  • Education$390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,095 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$150,802
Medicare patients
439
Services billed
1,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide75$98,104
EliquisApixaban97$81,184
OzempicSemaglutide59$64,007
TrulicityDulaglutide38$36,483
JardianceEmpagliflozin48$35,461
LinzessLinaclotide36$28,794
JanuviaSitagliptin Phosphate32$27,891
XareltoRivaroxaban23$27,224
MyrbetriqMirabegron31$25,061
TradjentaLinagliptin12$18,073
Repatha SureclickEvolocumab11$15,745
GlyxambiEmpagliflozin/Linagliptin16$13,408
Breo ElliptaFluticasone/Vilanterol22$13,030
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,142
Fiasp FlextouchInsulin Aspart (Niacinamide)11$10,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,109$134,587113 claims
PfizerEliquis$797$81,18497 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Synjardy Xr, Jentadueto Xr$223$80,301100 claims
Novo NordiskOzempic$526$64,00759 claims
AbbVieLinzess, Synthroid$1,098$36,842162 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$219$29,53247 claims
MerckJanuvia$87$27,89132 claims
Johnson & JohnsonXarelto$250$27,22423 claims
Astellas Pharma US IncMyrbetriq$247$25,06131 claims
NovartisEntresto$288$7,19911 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$34$3,628419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →